BAYRY - Bayer Aktiengesellschaft

Other OTC - Other OTC Delayed Price. Currency in USD
19.04
+0.61 (+3.31%)
At close: 3:59PM EST
Stock chart is not supported by your current browser
Previous Close18.43
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume880,740
Market Cap71.248B
Beta (3Y Monthly)1.01
PE Ratio (TTM)10.32
EPS (TTM)1.84
Earnings DateN/A
Forward Dividend & Yield0.81 (4.41%)
Ex-Dividend Date2018-05-25
1y Target Est30.70
Trade prices are not sourced from all markets
  • Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies
    Zacks4 days ago

    Aerie's (AERI) Eye Care Candidate to Enter Clinical Studies

    Aerie's (AERI) Investigational New Drug Application for AR-1105 for the treatment of macular edema due to retinal vein occlusion is accepted by the FDA. The candidate will now enter clinical studies.

  • Europe’s Most Important River Is Running Dry
    Bloomberg4 days ago

    Europe’s Most Important River Is Running Dry

    After a prolonged summer drought, the bustling traffic at one of the shallowest points on the Rhine ground to a halt for nearly a month late last year, choking off a critical transport artery. The impact damped Germany’s industrial machine, slowing economic growth in the third and fourth quarters. It was the latest sign of how even advanced industrial economies are increasingly fighting the effects of global warming.

  • Regeneron (REGN) Sails Steady on Label Expansion of Drugs
    Zacks6 days ago

    Regeneron (REGN) Sails Steady on Label Expansion of Drugs

    Regeneron's (REGN) performance has been steady in the past six months even as the overall industry declines.

  • The Wall Street Journal6 days ago

    [$$] Bayer Faces New Setback for Roundup Weedkiller in France

    BERLIN—Bayer AG’s fight to prove its recently-acquired weedkillers are safe faced a setback in Europe Tuesday as a French court revoked approval for one of its glyphosate-based products because it might cause cancer. The ruling effectively bans Bayer from selling the weedkiller in France. While the product is a small seller there, the court action could also give ammunition to plaintiffs who are suing the chemicals and pharmaceuticals company in the U.S. over Roundup and Ranger Pro weedkillers, which it inherited as part of its $63 billion takeover of Monsanto Co. last year.

  • Reuters7 days ago

    French court cancels Monsanto weedkiller permit on safety grounds

    A French court cancelled the licence for one of Monsanto's glyphosate-based weedkillers on Tuesday over safety concerns, placing an immediate ban on Roundup Pro 360 in the latest legal blow to the Bayer-owned business. Germany's Bayer (BAYGn.DE), which bought Monsanto for $63 billion last year, faces thousands of U.S. lawsuits by people who say its Roundup and Ranger Pro products caused their cancer. A court in Lyon in southeast France ruled that the approval granted by French environment agency ANSES in 2017 for Roundup Pro 360 had failed to take into account potential health risks.

  • French court cancels Monsanto weedkiller permit on safety grounds
    Reuters7 days ago

    French court cancels Monsanto weedkiller permit on safety grounds

    A French court canceled the license for one of Monsanto's glyphosate-based weedkillers on Tuesday over safety concerns, placing an immediate ban on Roundup Pro 360 in the latest legal blow to the Bayer-owned business. Germany's Bayer, which bought Monsanto for $63 billion last year, faces thousands of U.S. lawsuits by people who say its Roundup and Ranger Pro products caused their cancer. A court in Lyon in southeast France ruled that the approval granted by French environment agency ANSES in 2017 for Roundup Pro 360 had failed to take into account potential health risks.

  • Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer
    Zacks7 days ago

    Exelixis' Cabometyx Tablets Receive FDA Nod for Liver Cancer

    Exelixis (EXEL) gets FDA approval for Cabometyx tablets for patients with hepatocellular carcinoma (liver cancer), who have been previously treated with Nexavar.

  • After Monsanto patent ruling, Indian farmers hope for next-gen GM seeds
    Reuters11 days ago

    After Monsanto patent ruling, Indian farmers hope for next-gen GM seeds

    MUMBAI/NEW DELHI (Reuters) - Monsanto's victory this week in a patent case in India regarding genetically modified (GM) cotton seeds has raised hopes among farmers that the company will now launch its next-generation seeds. India approved Monsanto's GM cotton seed trait in 2002 and an upgraded variety in 2006, helping transform the country into the world's top producer and second-largest exporter of the fiber. Monsanto has said local seed companies have illegally attempted to "incorporate unauthorized and unapproved herbicide-tolerant technologies into their seeds".

  • Reuters11 days ago

    After Monsanto patent ruling, Indian farmers hope for next-gen GM seeds

    MUMBAI/NEW DELHI (Reuters) - Monsanto's victory this week in a patent case in India regarding genetically modified (GM) cotton seeds has raised hopes among farmers that the company will now launch its next-generation seeds. India approved Monsanto's GM cotton seed trait in 2002 and an upgraded variety in 2006, helping transform the country into the world's top producer and second-largest exporter of the fibre.

  • Monsanto patent victory seen as a boost for biotech investment in India
    Reuters13 days ago

    Monsanto patent victory seen as a boost for biotech investment in India

    NEW DELHI/MUMBAI (Reuters) - India's Supreme Court ruled on Tuesday that Monsanto can claim patents on its genetically modified (GM) cotton seeds, a victory for the U.S. company that is expected to encourage biotechnology firms to step up investment in the country. The decision on appeal overturns an earlier ruling by the Delhi High Court that Monsanto - the world's biggest seed maker, which has been bought by Germany's Bayer AG - could not claim patents on GM cotton seeds.

  • Market Exclusive13 days ago

    Market Morning: BlackRock Bullish, DowDuPont vs Bayer, AT&T Layoffs, iPhone Production Cut, Ahoy Futures

    BlackRock Isn’t Betting On A Bear BlackRock (NYSE:BLK) still loves tech stocks, not just in the United States, but in China as well. However, the top choice for the world’s largest asset manager is healthcare stocks, which offer defensiveness, income, and stability against a downturn, said BlackRock Chief Equity Strategist Kate Moore. She also believes […] The post Market Morning: BlackRock Bullish, DowDuPont vs Bayer, AT&T Layoffs, iPhone Production Cut, Ahoy Futures appeared first on Market Exclusive.

  • China's approval of DowDuPont soy poses challenge to Bayer
    Reuters13 days ago

    China's approval of DowDuPont soy poses challenge to Bayer

    China's approval of imports of a DowDuPont Inc (DWDP.N) genetically modified soybean puts rival Bayer AG (BAYGn.DE) on the defensive, investors and analysts said, as U.S. farmers will have a new choice when planting their most valuable agricultural export. Bayer-owned Monsanto has long dominated the $40 billion U.S. soybean market. The market has opened up, though, as Monsanto's Roundup Ready line of seeds - engineered to tolerate the weed killer glyphosate - has lost effectiveness as weeds develop tolerance to the chemical.

  • The Wall Street Journal13 days ago

    [$$] China’s GMO Ruling Hands U.S. Farmers New Tool in Battle Against Weeds

    China’s approval of new genetically engineered crops will open a new front in U.S. farmers’ long-running war against hard-to-kill weeds. The approval, outlined Tuesday by Chinese officials, clears the way for crop-seed and chemical maker DowDuPont Inc. to begin selling to U.S. farmers new soybean seeds modified to survive a powerful herbicide combination. The seeds are designed for farmers struggling to stop weeds that have developed resistance to other sprays. Resistant weeds are spreading across the U.S. Farm Belt, cutting into farmers’ harvests and boosting their spending on chemicals.

  • Reuters14 days ago

    Factbox: China approves new GMO soybean, corn and canola traits

    China approved five genetically modified crops for import on Tuesday, the first in about 18 months, as representatives from the Asian country and the United States met in face-to-face talks to try to resolve trade disagreements. Five other products, whose makers are known to be seeking approval of, were not given the green light by China's agriculture ministry, however. Some that were approved, including two canola varieties, had been waiting for six years.

  • Reuters14 days ago

    Factbox: China approves new GMO soybean, corn and canola traits

    China approved five genetically modified crops for import on Tuesday, the first in about 18 months, as representatives from the Asian country and the United States met in face-to-face talks to try to resolve trade disagreements. Five other products, whose makers are known to be seeking approval of, were not given the green light by China's agriculture ministry, however. Some that were approved, including two canola varieties, had been waiting for six years.

  • Reuters14 days ago

    Monsanto patent victory seen as a boost for biotech investment in India

    NEW DELHI/MUMBAI (Reuters) - India's Supreme Court ruled on Tuesday that Monsanto can claim patents on its genetically modified (GM) cotton seeds, a victory for the U.S. company that is expected to encourage biotechnology firms to step up investment in the country. The decision on appeal overturns an earlier ruling by the Delhi High Court that Monsanto - the world's biggest seed maker, which has been bought by Germany's Bayer AG (BAYGn.DE) - could not claim patents on GM cotton seeds.

  • Monsanto patent victory seen as a boost for biotech investment in India
    Reuters14 days ago

    Monsanto patent victory seen as a boost for biotech investment in India

    NEW DELHI/MUMBAI (Reuters) - India's Supreme Court ruled on Tuesday that Monsanto can claim patents on its genetically modified (GM) cotton seeds, a victory for the U.S. company that is expected to encourage biotechnology firms to step up investment in the country. The decision on appeal overturns an earlier ruling by the Delhi High Court that Monsanto - the world's biggest seed maker, which has been bought by Germany's Bayer AG - could not claim patents on GM cotton seeds.

  • Wiivv Partners with Dr. Scholl’s to Deliver Custom 3D Printed Insoles Directly within the United States
    Business Wire14 days ago

    Wiivv Partners with Dr. Scholl’s to Deliver Custom 3D Printed Insoles Directly within the United States

    Wiivv announced today at CES that it is partnering with Dr. Scholl’s, the category leader in foot care, to help expand the 112-year old brand’s business into custom 3D printed insoles, powered by Wiivv Fit Technology. Using a simple smartphone app, consumers can personalize their own design and order--on-demand from their living room--a Dr. Scholl’s Custom 3D printed insole mapped from 400 points on their feet. “Dr. Scholl‘s understands the importance of customization for a growing number of consumers.

  • Bayer Gets Rare Monsanto Reprieve With Cotton Seed Ruling
    Bloomberg14 days ago

    Bayer Gets Rare Monsanto Reprieve With Cotton Seed Ruling

    India’s Supreme Court ruled on Tuesday that Monsanto’s patent for Bt cotton seeds is valid, overturning a judgment by the High Court of Delhi that said certain items such as seeds, plants and animals can’t be patented. A two-judge bench, headed by Justice Rohinton F. Nariman, referred the matter to the lower court saying that all aspects related to Monsanto’s patents on genetically-modified seeds can be considered by the Delhi court. The ruling is a boost for Monsanto, which faced the risk of losing revenues without a claim over exclusive rights in India, as the company faces legal challenges in the U.S. over allegations that its Roundup weed killer can cause cancer as well as a backlash in Europe over genetically modified organisms.

  • Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy
    Reuters14 days ago

    Lilly makes $8 billion bet on drugs for rare cancers with Loxo Oncology buy

    The price represents a 68 percent premium to Loxo's Friday share price close, which some Wall Street analysts said was high for a company with only one drug on the market that it shares with a partner. Loxo shares surged 66 percent to $232.65, close to the offer price of $235 per share, and prompted stock price rises for a other small developers of targeted cancer therapies, including Array BioPharma, Blueprint Medicines Corp and Clovis Oncology Inc. Lilly shares rose 0.5 percent to $115.28. The cash deal comes on the heels of Bristol-Myers Squibb Co's agreement last week to buy Celgene Corp for $74 billion in the largest pharmaceutical deal ever, spurring investors' hopes of a new wave of large healthcare acquisitions.

  • Regeneron, Sanofi Restructure Immuno-Oncology Collaboration
    Zacks15 days ago

    Regeneron, Sanofi Restructure Immuno-Oncology Collaboration

    Regeneron (REGN) amends its existing agreement with Sanofi and selects two clinical-stage bispecific antibodies for the ongoing collaboration.

  • The Wall Street Journal17 days ago

    [$$] Bayer Shares Jump After Monsanto Weedkillers Court Ruling

    BERLIN—Bayer AG shares rose by more than 6% Friday after the German chemicals company scored a court victory in the run-up to jury trials over whether Monsanto Co. weedkillers can cause cancer. Bayer closed its $63 billion takeover of Monsanto last year, inheriting the St. Louis-based company’s Roundup weedkillers as well as potential legal liabilities. U.S. District Judge Vince Chhabria granted a request late Thursday from Bayer to stagger the submission of evidence in so-called bellwether trials, potentially limiting the evidence presented by the plaintiff’s lawyers to the jury.

  • U.S. judge stands by ruling to limit evidence in Roundup cancer trials
    Reuters18 days ago

    U.S. judge stands by ruling to limit evidence in Roundup cancer trials

    U.S. District Judge Vince Chhabria during a hearing in San Francisco federal court denied a plaintiff lawyer's request to review the decision, saying trials before him should focus on scientific evidence. Chhabria on Thursday granted Bayer unit Monsanto's request to split an upcoming trial into two phases. The order initially bars lawyers for plaintiff Edwin Hardeman from introducing evidence that the company allegedly attempted to influence regulators and manipulate public opinion.

  • Bayer Gains as Judge Limits Evidence in Roundup Cancer Cases
    Bloomberg18 days ago

    Bayer Gains as Judge Limits Evidence in Roundup Cancer Cases

    The first phase of three bellwether trials will be restricted to whether glyphosate, the main ingredient in Roundup, causes cancer, U.S. District Judge Vince Chhabria said in the ruling. The ruling is a positive sign as Bayer attempts to fend off lawsuits surrounding Roundup, which have been a drag on the stock since the Monsanto deal was complete last year. A U.S. court ruled that glyphosate caused a former school groundskeeper’s cancer, and Bayer faces more than 9,300 other plaintiffs.

  • CNBC18 days ago

    European stocks rally as the US and China agree to hold trade talks

    European markets got a boost after China's commerce ministry said the U.S. and China would hold trade talks on Jan. 7-8.